Intellia Therapeutics Management
Management criteria checks 2/4
Intellia Therapeutics' CEO is John Leonard, appointed in Jan 2018, has a tenure of 6.92 years. total yearly compensation is $11.66M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.82% of the company’s shares, worth $10.01M. The average tenure of the management team and the board of directors is 6.3 years and 9.7 years respectively.
Key information
John Leonard
Chief executive officer
US$11.7m
Total compensation
| CEO salary percentage | 5.7% |
| CEO tenure | 6.9yrs |
| CEO ownership | 0.8% |
| Management average tenure | 6.3yrs |
| Board average tenure | 9.7yrs |
Recent management updates
Recent updates
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 19Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Nov 11Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story
Nov 05Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Oct 25Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Sep 25We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Sep 07
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$522m |
| Jun 30 2024 | n/a | n/a | -US$509m |
| Mar 31 2024 | n/a | n/a | -US$486m |
| Dec 31 2023 | US$12m | US$660k | -US$481m |
| Sep 30 2023 | n/a | n/a | -US$462m |
| Jun 30 2023 | n/a | n/a | -US$453m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$10m | US$630k | -US$474m |
| Sep 30 2022 | n/a | n/a | -US$442m |
| Jun 30 2022 | n/a | n/a | -US$400m |
| Mar 31 2022 | n/a | n/a | -US$369m |
| Dec 31 2021 | US$10m | US$600k | -US$268m |
| Sep 30 2021 | n/a | n/a | -US$229m |
| Jun 30 2021 | n/a | n/a | -US$185m |
| Mar 31 2021 | n/a | n/a | -US$149m |
| Dec 31 2020 | US$4m | US$580k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$120m |
| Jun 30 2020 | n/a | n/a | -US$116m |
| Mar 31 2020 | n/a | n/a | -US$109m |
| Dec 31 2019 | US$904k | US$559k | -US$100m |
| Sep 30 2019 | n/a | n/a | -US$90m |
| Jun 30 2019 | n/a | n/a | -US$89m |
| Mar 31 2019 | n/a | n/a | -US$86m |
| Dec 31 2018 | US$10m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$83m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$3m | US$396k | -US$68m |
Compensation vs Market: John's total compensation ($USD11.66M) is above average for companies of similar size in the US market ($USD5.51M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Leonard (67 yo)
6.9yrs
Tenure
US$11,657,262
Compensation
Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.9yrs | US$11.66m | 0.82% $ 10.0m | |
| Executive VP & Chief Scientific Officer | 5.6yrs | US$4.19m | 0.019% $ 233.3k | |
| Executive VP | 3.5yrs | US$3.99m | 0.017% $ 213.8k | |
| Executive VP & Chief Medical Officer | 4.7yrs | US$4.26m | 0.029% $ 353.2k | |
| Founder & Member of Scientific Advisor Board | 10.6yrs | US$11.27m | no data | |
| Co-Founder | 10.6yrs | US$311.57k | no data | |
| Founder and Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data |
6.3yrs
Average Tenure
60yo
Average Age
Experienced Management: NTLA's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.4yrs | US$11.66m | 0.82% $ 10.0m | |
| Founder & Member of Scientific Advisor Board | no data | US$11.27m | no data | |
| Founder and Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | 9.7yrs | no data | no data | |
| Founder & Member of Scientific Advisor Board | 9.7yrs | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 9.9yrs | no data | no data | |
| Independent Chairman of the Board | 7.4yrs | US$499.94k | 0.010% $ 123.1k | |
| Independent Director | 1.7yrs | US$996.21k | 0.0067% $ 82.0k |
9.7yrs
Average Tenure
61yo
Average Age
Experienced Board: NTLA's board of directors are considered experienced (9.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:47 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Intellia Therapeutics, Inc. is covered by 44 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jack Allen | Baird |
| Huidong Wang | Barclays |